Compare BMEA & INVZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BMEA | INVZ |
|---|---|---|
| Founded | 2017 | 2016 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Auto Parts:O.E.M. |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 115.2M | 129.5M |
| IPO Year | 2021 | 2020 |
| Metric | BMEA | INVZ |
|---|---|---|
| Price | $1.73 | $0.35 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 3 |
| Target Price | ★ $9.83 | $2.68 |
| AVG Volume (30 Days) | 1.4M | ★ 4.1M |
| Earning Date | 05-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 69.19 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $29.61 |
| Revenue Next Year | N/A | $53.57 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.87 | $0.32 |
| 52 Week High | $2.99 | $2.54 |
| Indicator | BMEA | INVZ |
|---|---|---|
| Relative Strength Index (RSI) | 75.92 | 37.15 |
| Support Level | $1.23 | $0.35 |
| Resistance Level | $1.69 | $0.47 |
| Average True Range (ATR) | 0.11 | 0.02 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 72.03 | 45.18 |
Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.
Innoviz Technologies Ltd is a provider of LiDAR technology, serving as a Tier 1 supplier to the world's automotive manufacturers. Its LiDAR and perception software "see" further than a human driver and reduce the possibility of error, meeting the automotive industry's strictest expectations for performance and safety. Its sensors are designed to deliver exceptional range, resolution, and reliability, providing accurate 3D sensing in harsh weather conditions. Operating across the U.S., Europe, and Asia. Innoviz designs solutions for automotive OEMs, system integrators, municipalities, commercial enterprises, and others. InnovizSMART is an off-the-shelf solution for security, defense, and homeland security, intelligent traffic management, mobility, robotics, and aerial applications.